European Journal of Pharmacology 2008-12-28

Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.

Masashi Deguchi, Junji Kishino, Maki Hattori, Yoko Furue, Mina Yamamoto, Izumi Mochizuki, Motofumi Iguchi, Yosuke Hirano, Kanji Hojou, Morio Nagira, Yoshinori Nishitani, Kenichi Okazaki, Kiyoshi Yasui, Akinori Arimura

Index: Eur. J. Pharmacol. 601(1-3) , 163-70, (2008)

Full Text: HTML

Abstract

We discovered a novel dihydroorotate dehydrogenase (DHO-DH) inhibitor, S-2678 ([2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy) pyridin-3-yl] biphenyl-4-yl]-(3-methyl-2-butenyl) amine). Its inhibitory activity against DHO-DH was more potent than that of A77 1726, an active metabolite of the anti-rheumatic drug leflunomide. S-2678 suppressed immunoglobulin production in mouse B cells and human peripheral blood mononuclear cells in vitro, with little or no inhibition of cell proliferation, probably through inhibition of class switch recombination in the immunoglobulin heavy chain loci in B cells. In vivo antibody production induced by systemic immunization with ovalbumin was dramatically suppressed by oral administration of S-2678, without any toxicological signs. However, S-2678 did not affect T-cell activation in vitro, and cytokine production induced by intravenous anti-CD3 antibody in mice. S-2678 did not affect host defense in a mouse model of Candida infection, whereas leflunomide severely impaired it. In conclusion, S-2678 selectively acts on B cells, resulting in antibody production, which suggests that it is useful for the treatment of humoral immunity-related diseases.